The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

Johnson & Johnson (NYSE:JNJ) researches, develops, manufactures and sells various products in the health care field worldwide ...

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 consecutive years, making it a Dividend King. Between Johnson & Johnson's strong ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the stock has risen by around just 3%. This is not the type of investment ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

Johnson & Johnson (JNJ) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

Johnson & Johnson (NYSE:JNJ) has had a rough three months with its share price down 11%. However, stock prices are usually driven by a company’s financials over the long term, which in this case ...